EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer

Dae-Won Lee, Yoojoo Lim, Hwang-Phill Kim, Su Yeon Kim, Hanseong Roh, Jun-Kyu Kang, Kyung-Hun Lee, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park und 3 weitere

Cancer Research and Treatment · 15.07.2023 · 55 (3) · 927-938

DOI: 10.4143/crt.2023.268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.07.2023. Verfasst von Dae-Won Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colonic Neoplasms, Cell-Free Nucleic Acids, Rectal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Circulating tumor DNA (ctDNA) is emerging as a valuable non-invasive tool to identify tumor heterogeneity and tumor burden. This study investigated ctDNA dynamics in metastatic colorectal cancer patients treated with regorafenib.Materials and Methods In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease were sequenced using a targeted next-generation sequencing platform which included 106 genes.

Results

A total of 285 blood samples from 110 patients were analyzed. Higher baseline cfDNA concentration was associated with worse progression-free survival (PFS) and overall survival (OS). After 2 cycles of treatment, variant allele frequency (VAF) in the majority of ctDNA mutations decreased with a mean relative change of –31.6%. Decreases in the VAF of TP53, APC, TCF7L2, and ROS1 after 2 cycles of regorafenib were associated with longer PFS. We used the sum of VAF at each time point as a surrogate for the overall ctDNA burden. A reduction in sum (VAF) of ≥ 50% after 2 cycles was associated with longer PFS (6.1 vs. 2.7 months, p=0.002), OS (11.3 vs. 5.9 months, p=0.001), and higher disease control rate (86.3% vs. 51.1%, p < 0.001). VAF of the majority of the ctDNA mutations increased at the time of disease progression, and VAF of BRAF increased markedly.

Conclusion

Reduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColonic NeoplasmsCell-Free Nucleic AcidsRectal NeoplasmsColorectal NeoplasmsHumansProtein-Tyrosine KinasesProto-Oncogene ProteinsTreatment OutcomeBiomarkers, TumorMutationPhenylurea CompoundsPyridines

Stichwörter der Autor:innen

Colorectal neoplasmsLiquid biopsyRegorafenibctDNA

Substanzen

Circulating Tumor DNAProtein-Tyrosine KinasesProto-Oncogene ProteinsCell-Free Nucleic AcidsBiomarkers, TumorregorafenibPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • IMBdx, Inc., Seoul, Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Surgery, Seoul National University Hospital, Seoul, Korea.
  • Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.

Förderung

  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare

Zitieren

APA

Lee, D. W., Lim, Y., Kim, H. P., Kim, S. Y., Roh, H., Kang, J. K., Lee, K. H., Kim, M. J., Ryoo, S. B., Park, J. W., Jeong, S. Y., Park, K. J., Kang, G. H., Han, S. W., & Kim, T. Y. (2023). Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer. Cancer Research and Treatment, 55(3), 927-938. https://doi.org/10.4143/crt.2023.268

Vancouver

Lee DW, Lim Y, Kim HP, Kim SY, Roh H, Kang JK, et al. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer. Cancer Research and Treatment. 2023;55(3):927-938. doi:10.4143/crt.2023.268

BibTeX
@article{Lee2023,
  author = {Lee, Dae-Won and Lim, Yoojoo and Kim, Hwang-Phill and Kim, Su Yeon and Roh, Hanseong and Kang, Jun-Kyu and Lee, Kyung-Hun and Kim, Min Jung and Ryoo, Seung-Bum and Park, Ji Won and Jeong, Seung-Yong and Park, Kyu Joo and Kang, Gyeong Hoon and Han, Sae-Won and Kim, Tae-You},
  title = {Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer},
  journal = {Cancer Research and Treatment},
  year = {2023},
  volume = {55},
  number = {3},
  pages = {927--938},
  doi = {10.4143/crt.2023.268}
}
Kostenlos starten →